Matt Phipps
Stock Analyst at William Blair
(1.17)
# 3,785
Out of 5,124 analysts
24
Total ratings
41.18%
Success rate
-7.42%
Average return
Main Sectors:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DVAX Dynavax Technologies | Downgrades: Market Perform | n/a | $15.38 | - | 1 | Dec 24, 2025 | |
| EVMN Evommune | Initiates: Outperform | n/a | $17.12 | - | 1 | Dec 1, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $6.30 | - | 3 | Oct 17, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | n/a | $4.00 | - | 1 | Oct 16, 2025 | |
| INSM Insmed | Initiates: Outperform | n/a | $174.04 | - | 1 | Aug 20, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Market Perform | n/a | $11.15 | - | 2 | Jul 14, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | n/a | $1.83 | - | 2 | Jul 7, 2025 | |
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $1.47 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $15.31 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $30.80 | - | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $20.36 | - | 1 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $27.15 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.20 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.35 | - | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $53.94 | - | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.80 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.87 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $175.99 | - | 2 | Jun 8, 2021 |
Dynavax Technologies
Dec 24, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $15.38
Upside: -
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: n/a
Current: $17.12
Upside: -
Kezar Life Sciences
Oct 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $6.30
Upside: -
Climb Bio
Oct 16, 2025
Initiates: Outperform
Price Target: n/a
Current: $4.00
Upside: -
Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $174.04
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $11.15
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.83
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.47
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $15.31
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $30.80
Upside: -
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $20.36
Upside: -
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $27.15
Upside: -
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $12.20
Upside: -
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $10.35
Upside: -
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $53.94
Upside: -
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $13.80
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.87
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $175.99
Upside: -